Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Licenses Power3 Neuro Biomarkers

NEW YORK (GenomeWeb News) – Transgenomic said on Monday that it has finalized an agreement with Power3 Medical Products giving it rights to Power3's neurodegenerative biomarkers.

The exclusive license gives Transgenomic the rights to certain biomarkers including the NuroPro, a proposed Alzheimer's and Parkinson's diagnostic based on Power3 Medical's proteomics platform, in the US and in certain international markets. Under the agreement, Transgenomic said it will pay Power3 Medical an up-front license fee, milestone payments, royalties, and it will provide development funding and other resources.

Transgenomic will offer the test through its CLIA-certified lab, through which it also offers molecular diagnostic tests for mitochondrial disorders, oncology, hematology, molecular pathology, and inherited disorders.

NuroPro monitors the concentration of a panel of blood serum protein biomarkers and assigns a probability score to reflect the chance that a patient may have a neurodegenerative disease. Doctors can use it to help distinguish patients with Alzheimer's, Parkinson's, or Lou Gehrig's diseases from healthy patients or those with other neurological diseases.

Power3 Medical currently is conducting prospective clinical validation studies of NuroPro in Alzheimer's and Parkinson's diseases, with results indicating sensitivities and specificities of 85 percent to 95 percent for both disorders.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.